Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 3.05B 3.47B 2.84B 2.61B 4.88B 332B 5B 33.71B 13.18B 164B 13.01B 12.73B 568B P/E 2026 *
21.3x
P/E 2027 * 17.6x
Enterprise Value 3.03B 3.45B 2.83B 2.6B 4.86B 330B 4.98B 33.53B 13.11B 163B 12.94B 12.66B 565B EV / Sales 2026 *
3.93x
EV / Sales 2027 * 3.33x
Free-Float
31.63%
Yield 2026 *
1.62%
Yield 2027 * 1.96%
1 day-1.08%
1 week+6.39%
Current month+3.54%
1 month+2.13%
3 months-24.07%
6 months-17.65%
Current year-5.29%
1 week 58.2
Extreme 58.2
59.95
1 month 53.15
Extreme 53.15
59.95
Current year 53.15
Extreme 53.15
86.6
1 year 51.85
Extreme 51.85
86.6
3 years 43.8
Extreme 43.8
90.75
5 years 35.64
Extreme 35.64
90.75
10 years 35.64
Extreme 35.64
90.75
Manager TitleAgeSince
Chief Executive Officer - 2007-07-26
Director of Finance/CFO - 2000-12-31
Chief Operating Officer - -
Director TitleAgeSince
Chairman - 2021-07-16
Director/Board Member - 2007-07-26
Director/Board Member - 2007-07-26
Change 5-day change 1-year change 3-year change Capi.($)
-1.17%+6.39% - - 3.47B
-4.12%-1.90%+53.06%+155.94% 1,079B
-3.58%-1.47%+52.73%+52.49% 640B
-2.80%-0.47%+35.08%+70.96% 465B
-2.12%+1.00%+35.98%+30.45% 353B
-2.14%-0.61%+33.53%+39.32% 301B
-2.82%+0.69%+11.11%+14.21% 271B
-2.15%+3.22%+1.72%-39.46% 228B
-1.89%+2.12%+25.89%+62.02% 209B
-2.71%-1.31%+12.53%+69.62% 165B
Average -2.58%+3.22%+29.07%+50.62% 412.19B
Weighted average by Cap. -3.11%+3.63%+38.00%+74.60%

Financials

2026 *2027 *
Net sales 772M 878M 720M 661M 1.24B 84.12B 1.27B 8.54B 3.34B 41.63B 3.3B 3.23B 144B 891M 1.01B 831M 763M 1.43B 97.1B 1.46B 9.86B 3.86B 48.05B 3.81B 3.72B 166B
Net income 129M 146M 120M 110M 206M 14.01B 211M 1.42B 556M 6.93B 549M 537M 23.97B 174M 198M 162M 149M 279M 18.95B 286M 1.92B 753M 9.38B 743M 727M 32.42B
Net Debt -16.21M -18.45M -15.13M -13.89M -26M -1.77B -26.64M -179M -70.18M -875M -69.28M -67.77M -3.02B -81.51M -92.76M -76.08M -69.82M -131M -8.88B -134M -902M -353M -4.4B -348M -341M -15.2B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
2,470
Date Price Change
26-07-28 59.95 +1.01%
26-07-28 €59.35 -0.17%
26-07-27 €59.45 +0.59%
26-07-24 €59.10 +0.68%
26-07-23 €58.70 +4.17%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
59.55EUR
Average target price
74.36EUR
Spread / Average Target
+24.86%

Quarterly revenue - Rate of surprise